French health authorities have approved the use of an anti-body treatment made by AstraZeneca for high-risk people who show resistance to vaccines against coronavirus.
The independent public health body HAS Friday night announced “a greenlight for the preventive use of Evusheld... for patients with a very high-risk of contracting a severe form of Covid-19”.
Evusheld, developed by the British-Swedish pharma company, this week received emergency use authorisation in the United States for adults and children aged 12 and above.
The French approval is for adults only.
Evusheld, which is made from a combination of two monoclonal antibodies, is administered in two injections.
Monoclonal antibodies — which recognise a specific molecule of the target virus or bacteria — are synthetic versions of natural antibodies.
Unlike most other Covid treatments, which are given to already hospitalised patients to prevent serious illness, Evusheld is for people who have yet to be infected but may not mount an adequate immune response.
HAS warned of cardiovascular risks identified during clinical trials and recommended the drug not be given to cases with two or more risk factors such as diabetes and obesity.
He played 86 times for his country, scoring eight goals, the most famous of which, an 85th-minute penalty against Argentina
Afzal Basira defeated Rajgan Cricket Club by 26 runs to claim the crown
The 57,000 sqm facility incorporates advanced technologies that include automated sort systems
The couple, who tied the knot in 2017, had their first child Vamika in 2021
Report notes that the GCC banking sector has experienced steady growth due to infrastructure projects, economic diversification efforts
The schedule is yet to be announced as the league coincides with India's general elections
Parents must register their child and obtain the necessary documents within 120 days of the birth to avoid paying penalties